Wednesday, August 10, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

USAMRIID Study Leads to Approval of New Smallpox Vaccine

by Global Biodefense Staff
October 20, 2019
boxes of packaged smallpox vaccine Jynneos

New smallpox vaccine, JYNNEOS (Image credit: Bavarian Nordic)

A new vaccine approved in the U.S. on Sept. 24 prevents both smallpox and the related disease monkeypox in adults. Marketed under the brand name JYNNEOS, the vaccine was developed by biotechnology firm Bavarian Nordic and tested by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

Current smallpox research focuses on developing vaccines, drugs and diagnostic tests to protect against the virus should it be used as an agent of bioterrorism. JYNNEOS was developed as an alternative to the current U.S. licensed smallpox vaccine, ACAM2000, which cannot be used by people with certain health conditions.

To assess the vaccine’s effectiveness, USAMRIID study director Phillip R. Pittman, M.D., led a clinical trial in collaboration with the U.S. Defense Health Agency (DHA). His team enrolled U.S. service members stationed in South Korea in the study, placing 440 participants into one of two groups. While the first group received two doses of JYNNEOS 28 days apart, the second group received a single dose of ACAM2000. Participants receiving JYNNEOS had a superior immune response and fewer side effects compared to those who received ACAM2000.

“In addition to its public health importance, this vaccine will have a direct impact on improving force health protection for U.S. troops who are required to be immunized against smallpox.”

Col. E. Darrin Cox, Commander of USAMRIID

While enhancing the medical readiness of U.S. fighting forces, the new smallpox vaccine also has been selected for inclusion in the Centers for Disease Control and Prevention’s (CDC) Strategic National Stockpile, the nation’s largest supply of potentially life-saving pharmaceuticals and medical supplies for use in a public health emergency.

Smallpox is an ancient disease that is highly contagious and often fatal in humans. Symptoms include fever, body aches, and a skin rash that develops into fluid-filled lesions. The smallpox virus is spread through saliva and droplets from the respiratory tract, or by direct or indirect contact with the virus as it is shed from skin lesions. The virus also can be spread through other body fluids and contaminated clothing or bedding.

Monkeypox is a rare disease that does not occur naturally in the U.S. It begins with fever, headache, muscle aches and exhaustion and is typically milder than smallpox, though it can be fatal in some cases. Monkeypox is transmitted to people from wild animals, such as rodents and primates. In 2003, the U.S. experienced an outbreak of monkeypox, which was the first time human monkeypox was reported outside of Africa.

Tags: Editor PickMonkeypoxPoxvirusesSelect AgentsSmallpoxStrategic National StockpileUSAMRIIDVaccines

Related Posts

Influenza Transmission Spikes During Social Gatherings
Medical Countermeasures

New Universal Flu Vaccine Offers Broad Protection Against Influenza A Virus Infections

July 17, 2022
Adverse Events After Simultaneous COVID-19 mRNA Booster, Flu Vaccination
Medical Countermeasures

Adverse Events After Simultaneous COVID-19 mRNA Booster, Flu Vaccination

July 16, 2022
US Starts Clinical Trial for mRNA Nipah Virus Vaccine
Medical Countermeasures

US Starts Clinical Trial for mRNA Nipah Virus Vaccine

July 11, 2022
Targeting Poxviruses with Messenger RNA Technology
Medical Countermeasures

Targeting Poxviruses with Messenger RNA Technology

July 11, 2022
Load More

Latest News

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast

July 27, 2022
Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids

Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids

July 17, 2022
Influenza Transmission Spikes During Social Gatherings

New Universal Flu Vaccine Offers Broad Protection Against Influenza A Virus Infections

July 17, 2022
Long COVID: National Academies’ Panel Examines Long-Term Health Effects of COVID-19

Long COVID: National Academies’ Panel Examines Long-Term Health Effects of COVID-19

July 17, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy